Boryung said Wednesday that it has signed a sales agreement with Baxter Korea to sell inhalation anesthesia Suprane Solution and blood substitute Plasma Lyte 148 Inj 1,000ml in the domestic market.
Suprane (desflurane), the original drug developed by Baxter, is a leading inhalation anesthetic used to induce and maintain anesthesia during surgery. Suprane provides rapid and accurate control of the depth of anesthesia and has the lowest solubility of any inhaled anesthetic, enabling rapid and predictable patient recovery after anesthesia.
Plasma Lyte 148 Inj is Baxter's original fluid solution, a physiologically balanced blood substitute with sodium, magnesium, and potassium levels similar to human plasma. It is indicated for the replenishment and correction of extracellular fluid in cases of decreased circulating blood volume and interstitial fluid and for the correction of metabolic acidosis.
Plasma Lyte 148 Inj is a fluid therapy that improves the treatment effectiveness of critically ill patients in Korea by reducing mortality compared to normal saline in patients with systemic inflammatory response syndrome (SIRS) and reducing the risk of complications in patients undergoing major open surgery. It also has the advantage of not containing calcium so that it can be administered before, during, and after transfusion.
"Suprane speeds up postoperative recovery in geriatric anesthesia, cardiopulmonary anesthesia, transplantation anesthesia, and anesthesia cases requiring long-term surgery," said Dr. Yeon Jun-heum, president of the Korean Society of Anesthesiologists and professor of pain medicine at Inje University Sanggye Paik Hospital. "'Plasma Lyte 148 Inj is an important drug in anesthesiology because its electrolyte composition and osmolarity concentration are similar to plasma, which improves patient outcomes after surgery."
The agreement expands Boryung's portfolio of anesthesiology drugs and further strengthens its business capabilities in this area. Boryung has been conducting sales and marketing activities in the anesthesiology market based on the anti-emetic Naseron (ramosetron) and the muscle relaxant prodrug Breathon (sugammadex). Currently, Naseron holds the No. 1 market share in the ramosetron component market, and Breathon holds the No. 2 market share in the sugammadex component market.
Boryung will focus on expanding the market share of both products based on its dedicated anesthesiology organization and academic sales and marketing. Last Saturday, Boryung also held an “Anesthesiology Symposium” at the Grand Chosun Hotel in Busan as part of its full-scale marketing campaign. Boryung has also co-promoted Olimel N9E, a comprehensive nutritional fluid, with Baxter since 2020.
"Suprane and Plasma Lyte 148 Inj are important drugs for the safety and quality management of surgical patients undergoing anesthesia," said Jung Woong-je, head of the RX Division at Boryung. "We plan to focus on strengthening our market share in the anesthesiology area based on these two products."